In this issue:
Pan-cancer predictive biomarkers for CAR T-cell therapy
Site-specific engineering to reprogramme T-cells in vivo
Autologous CAR T-cell therapy targeting 5 tumour-associated antigens in pancreatic cancer
Corticosteroids & CAR T-cell-induced CRS in multiple myeloma
T-cell receptor-like CAR-T targeting mesothelin in ovarian cancer
Concomitant medications & Claudin18.2-specific CAR-T responses in gastric cancer
Varnimcabtagene autoleucel in pre-B-ALL
Brexucabtagene autoleucel in BTKi-naïve R/R MCL
Time of infusion & outcomes of CAR T-cell therapy in large B-cell lymphoma
CD19/22 CAR T-cell therapy ± ASCT in R/R DLBCL
Please login below to download this issue (PDF)